J Transl Med. 2014 Aug 21;12(1):226
Read more Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells J Transl Med. 2014 Aug 21;12(1):226. Wang J, Ma X, Jones HM, Chan L, Song F, Zhang W, Bae-Jump VL, Zhou C. Epithelial ovarian carcinoma is the most lethal gynecological cancer due to its silent onset and recurrence with resistance to chemotherapy. Overexpression of oncogene c-Myc is one of the most frequently encountered events present in ovarian carcinoma. Disrupting the function of c-Myc and its downstream target genes is a promising strategy for cancer therapy. Our objective was to evaluate the potential effects of small-molecule [...]